fentaNYL Citrate Injectable Solution, Narcotic, CII, 1250 mcg/25mL (50 mcg per mL), 25 mL, wells pharma of Houston, NDC 73702-204-25.
Published May 6, 2026 · Recall initiated: April 1, 2026
Summary
FDA records drug Class II recall D-0505-2026, published May 6, 2026 and initiated April 1, 2026. Recalling firm: Wells Pharma of Houston LLC; Status: Ongoing; Reported quantity: 50 syringes; Lot: Lot 011226204250063, Exp Date 05/14/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
cGMP deviations.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Wells Pharma of Houston LLC
- Distributor
- U.S. Nationwide.
- Lot
- Lot 011226204250063, Exp Date 05/14/2026
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAfentaNYL Citrate injectable Solution in 0.9% Sodium Chloride, Narcotic, (2500 mcg/ 250 mL) (10 mcg per mL),May 6, 2026
- FDAKetamine Hydrochloride Injectable Solution, 50mg/ml, (50 mg per mL) Volume: 1 mL, 5265 Kitty Drive, Houston,May 6, 2026
- FDAfentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 1000 mcg/50mL (20 mcg per mL), well pharma ofMay 6, 2026
- FDAfentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDCMay 6, 2026
- FDAfentaNYL Citrate Injectable Solution, NARCOTIC, Cii, 1000 mcg/100 mL (10 mcg per mL), 100 mL bag, Wells PharmaMay 6, 2026
- FDAPhenylephrine Hydrochloride Injectable Solution, 40mg, 250*mL Bag, wells pharma of Houston, NDC 73702-122-03May 6, 2026
Questions about this recall
Was fentaNYL Citrate Injectable Solution, Narcotic, CII, 1250 mcg/25mL (50 mcg per mL), 25 mL, wells pharma of Houston, NDC 73702-204-25. recalled?
Yes. FDA published recall D-0505-2026 on May 6, 2026. Reported hazard: cGMP deviations.
What should I do if I have this product?
Voluntary: Firm initiated · Letter